Prestige Consumer Healthcare (PBH) AI Stock Analysis

• Market Cap: $3.65B
• Dividend Yield: N/A
• Average Volume (3M): 429.01K
• Price to Earnings (P/E): 17.3
• Beta (1Y): 0.36
• Revenue Growth: 1.10%
• EPS Growth: 2.65%
• Country: US
• Employees: 600
• Sector: Healthcare
• Sector Strength: 38
• Industry: Medical - Distribution
• EPS (TTM): 0.95
• Shares Outstanding: 49,233,437
• 10 Day Avg. Volume: 383,177
• 30 Day Avg. Volume: 429,011
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.44
• Enterprise Value/Revenue: 4.61
• Enterprise Value/Gross Profit: 8.28
• Enterprise Value/Ebitda: 14.85
• 1Y Price Target: $87.50
• Price Target Upside: 17.92% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 69 Neutral
• Price Target: $90.00 ▲(21.29% Upside)

The overall stock score reflects strong financial performance and positive earnings guidance. However, technical analysis indicates bearish momentum, and moderate valuation limits the upside potential. The lack of a dividend yield might deter some investors.

Positive Factors

Brand Performance

Prestige is executing its brand building playbook well, resulting in steady organic sales improvement, strong cash generation, and dependable earnings growth.

Debt Management

Strong free cash flow enabled further debt reduction and share repurchases.

Revenue Growth

Fiscal fourth-quarter organic sales were up 7% on broad-based strength, including the women’s health and gastrointestinal categories in the U.S and international.

Negative Factors

Guidance and Projections

Management provided initial fiscal 2026 guidance for sales and EPS consistent with consensus.

Market Competition

There is room for shares to appreciate with earnings and by narrowing its multiple discount to certain other stable growers in the consumer packaged goods and healthcare space.

Revenue Sources

Management highlighted strong performance internationally and sequential improvement in Clear Eyes revenues driving stronger-than-expected sales.

Prestige Consumer Healthcare Business Overview & Revenue Model

Company Description

Prestige Consumer Healthcare Inc. is a consumer healthcare company engaged in the development, manufacturing, and marketing of over-the-counter (OTC) healthcare products. The company operates primarily in the healthcare sector, focusing on providing effective and accessible self-care solutions. Its core product offerings include a wide range of OTC medications and health-related products, such as pain relievers, digestive products, and eye care items, targeting common health issues among consumers.

How the Company Makes Money

Prestige Consumer Healthcare makes money by developing and selling a diverse portfolio of over-the-counter healthcare products. The company's revenue model primarily relies on the sales of these products through various distribution channels, including pharmacies, supermarkets, and online retailers. Key revenue streams include the sale of branded products in categories such as pain relief, gastrointestinal health, and eye care. Prestige Consumer Healthcare benefits from strategic partnerships with retailers and distributors to maximize market reach and increase product availability. The company's earnings are also influenced by factors such as consumer demand for self-care products, brand recognition, and effective marketing strategies.

Prestige Consumer Healthcare Financial Statement Overview

Summary

Prestige Consumer Healthcare demonstrates solid financial health across income, balance sheet, and cash flow metrics. The company shows consistent revenue growth and strong profitability margins, while maintaining a low leverage position. Cash flow generation is stable, supporting operational and financial flexibility.

Income Statement

Prestige Consumer Healthcare has shown consistent revenue growth, with a 1.1% increase from 2024 to 2025. The gross profit margin remains strong at 55.8% in 2025, reflecting effective cost management. However, the EBIT margin slightly decreased from 30.4% in 2024 to 29.6% in 2025, indicating some pressure on operational efficiency. The net profit margin improved slightly to 18.9% in 2025, highlighting enhanced profitability.

Balance Sheet

The company's financial stability is solid with a low debt-to-equity ratio of 0.03 in 2025, demonstrating effective debt management. The equity ratio is strong at 53.9%, indicating a healthy proportion of equity financing. Return on equity stands at 11.7%, showing reasonable profitability for shareholders. The improvement in equity and reduction in total liabilities over the years reflect a strengthening balance sheet.

Cash Flow

Operating cash flow increased slightly to $251.5 million in 2025, supporting ongoing operations effectively. Free cash flow growth is modest at 1.6% year-over-year, but the free cash flow to net income ratio is robust at 1.13, indicating strong cash generation relative to profits. The stable cash flow trends suggest efficient cash management and operational stability.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.14B	1.13B	1.13B	1.09B	943.37M
Gross Profit	634.46M	624.45M	625.29M	620.65M	547.47M
EBITDA	353.11M	373.86M	14.19M	351.61M	310.38M
Net Income	214.60M	209.34M	-82.31M	205.38M	164.68M
Balance Sheet
Total Assets	3.40B	3.32B	3.35B	3.67B	3.43B
Cash, Cash Equivalents and Short-Term Investments	97.88M	46.47M	58.49M	27.18M	32.30M
Total Debt	1.04B	1.14B	1.37B	1.51B	1.51B
Total Liabilities	1.57B	1.66B	1.91B	2.09B	2.07B
Stockholders Equity	1.83B	1.66B	1.45B	1.58B	1.36B
Cash Flow
Free Cash Flow	243.29M	239.38M	221.93M	250.28M	213.36M
Operating Cash Flow	251.51M	248.93M	229.72M	259.92M	235.61M
Investing Cash Flow	-17.45M	-20.11M	-11.58M	-256.51M	-22.24M
Financing Cash Flow	-182.07M	-241.01M	-185.85M	-7.57M	-279.42M

Prestige Consumer Healthcare Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 74.20
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PBH, the sentiment is Negative. The current price of 74.2 is below the 20-day moving average (MA) of 75.95, below the 50-day MA of 80.56, and below the 200-day MA of 81.12, indicating a bearish trend. The MACD of -1.72 indicates Negative momentum. The RSI at 32.31 is Neutral, neither overbought nor oversold. The STOCH value of 21.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PBH.

Prestige Consumer Healthcare Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PDCO	70 Outperform	$2.77B	20.21	14.15%	―	-0.85%	-23.40%
PBH	69 Neutral	$3.65B	17.28	12.30%	―	1.10%	2.65%
CAH	63 Neutral	$37.23B	24.36	-43.80%	1.30%	0.78%	183.45%
HSIC	61 Neutral	$7.89B	20.85	11.18%	―	2.29%	14.98%
Sector *	51 Neutral	$7.39B	0.57	-62.87%	2.36%	15.63%	-0.87%
GRDN	47 Neutral	$1.34B	―		―	―	―
OMI	44 Neutral	$498.76M	―	-49.91%	―	2.84%	-828.91%

Prestige Consumer Healthcare Corporate Events

Prestige Consumer Healthcare Reports Record Fiscal Year Revenue

On May 8, 2025, Prestige Consumer Healthcare reported record revenue and earnings for the fiscal year ending March 31, 2025, with a revenue of $1,137.8 million and a diluted EPS of $4.29. The company saw significant growth in its international business and North American categories, particularly in gastrointestinal and women’s health, and achieved a strong free cash flow, which facilitated share repurchases and debt reduction. Looking ahead to fiscal 2026, Prestige anticipates organic revenue growth of 1% to 2% and EPS growth, despite inflationary challenges, leveraging its diverse product portfolio and agile operating model to maintain consistent financial performance and shareholder value.